Health Canada has approved Sohonos (palovarotene), making it the first-ever treatment for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder that turns soft tissue into bone.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.